Logo

Pfizer and BioNTech Initiate P-I Study of mRNA-Based Combination Vaccine for the Treatment of COVID-19 and Influenza

Share this
Pfizer and BioNTech Initiate P-I Study of mRNA-Based Combination Vaccine for the Treatment of COVID-19 and Influenza

Pfizer and BioNTech Initiate P-I Study of mRNA-Based Combination Vaccine for the Treatment of COVID-19 and Influenza

Shots:

  • The first participant has been dosed in a P-I trial evaluating the safety, tolerability, and immunogenicity of a nucleoside modRNA-based combination vaccine in 180 healthy volunteers aged 18 through 64yrs. against COVID-19 and influenza across the US
  • The single-dose vaccine is a combination of Pfizer’s quadrivalent modRNA-based influenza vaccine qIRV, currently in P-III clinical development & Omicron-adapted bivalent COVID-19 vaccine based on BioNTech’s mRNA platform technology
  • The new development program builds on the companies’ success in developing the first approved and most widely used mRNA vaccine for COVID-19. Both companies will share the development costs

Ref: Pfizer Image: Pfizer 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions